Recommended

Nanoscope signals potential gene therapy advance in retinal disease
Key factors shaping pharmaceutical formulation
ICH opens consultation on Q3E drug impurities guideline
Pharma cautious about direct-to-consumer drug sales
WuXi wins Irish authorisation for biologic manufacturing
Sanofi’s diabetes immunotherapy gains UK first
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

Standout breast cancer trial outcomes for Roche small molecule therapy

1
SHARES

The Itovebi-based combination therapy was recently granted US FDA approval for a common metastatic breast cancer.

Roche Itovebi breast cancer

Credit: Judith Linine / Shutterstock.com

New Phase III analysis reports that an Itovebi TM (inavolisib)-based combination treatment more than doubled progression-free survival in advanced breast cancer patients. The treatment lowered disease risk worsening or death by 57 percent, according to the analysis from Roche’s Phase III INAVO120 study. This was in comparison to palbociclib and fulvestrant only.

This study investigated Itovebi (inavolisib) in combination with (Ibrance®) palbociclib and fulvestrant.

Earlier this month, the US Food and Drug Administration (FDA) approved Roche’s Itovebi together with palbociclib and fulvestrant.

 

Reserve your FREE place

 


Explore innovative, purpose-built AI solutions that elevate compliance and efficiency in quality and manufacturing operations.

17 September 2025 | 10:00 AM BST | FREE Webinar

In this webinar, find out how AI tools such as customised large language models (LLMs), orchestrated services, and human-in-the-loop design can streamline processes, enhance training, and improve efficiencies.

Don’t miss your chance to learn from industry experts – Register Now – It’s Free!

 

The treatment was authorised for adults as a first-line treatment for HR-positive, HER2-negative breast cancer with a PIK3CA mutation. The combination therapy is indicated for these patients who have disease recurrence on or after receiving adjuvant endocrine therapy, according to Roche.

Itovebi-based regimen – a viable option as a new first-line standard of care

“this Itovebi-based regimen could become a new first-line standard of care for [HR-positive, HER2-negative breast cancer with a PIK3CA mutation]”

“With a doubling of progression-free survival and consistent benefits in people whose disease had spread to multiple challenging-to-treat locations, including the liver and lungs, these INAVO120 data are significant for patients,” commented Dr Komal Jhaveri, section Head for the endocrine therapy research portfolio and clinical director of the early drug development service at Memorial Sloan Kettering Cancer Center and a principal investigator of the INAVO120 study.

“I’m confident this Itovebi-based regimen could become a new first-line standard of care for this patient population with one of the most commonly mutated genes in metastatic breast cancer, associated with a poor prognosis,” Dr Komal Jhaveri asserted.

The PIK3CA mutation is present in approximately 40 percent of HR-positive metastatic breast cancers, research shows.

Development of novel breast cancer therapies

Earlier this month, Genentech (a member of the Roche Group) announced that the company planned to acquire next-generation treatments for breast cancer as part of a deal with Regor Pharmaceuticals.

Share via
Share via